Fluticasone propionate controlled release - Eupraxia Pharmaceuticals

Drug Profile

Fluticasone propionate controlled release - Eupraxia Pharmaceuticals

Alternative Names: EP 104IAR; Fluticasone propionate - Eupraxia

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Eupraxia Pharmaceuticals
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules; Steroids
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Osteoarthritis in Canada (Intra-articular) (NCT02609126)
  • 15 Mar 2016 Biomarkers information updated
  • 27 Nov 2015 Preclinical trials in Osteoarthritis in Canada (Injection) prior to November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top